What to Do Next: Managing ART Failure in People With HIV

Assessment of Needs

This case-based webinar, led by Michael S. Saag, MD, will discuss the management of antiretroviral therapy (ART) in individuals with HIV in whom their first antiretroviral regimen has failed and those for whom numerous treatment regimens have failed. The webinar will also discuss when and how to use resistance testing when managing ART failure.

Learning Objectives

 Upon completion of this activity, learners will be able to: 

• Identify antiretroviral therapy failure and subsequent treatment options in patients with HIV, including individuals on their first regimen as well as those on second regimens and beyond
• Design an effective regimen for multidrug regimen failure
• Describe when and how clinicians use resistance testing for the management of patients with HIV

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Thursday, September 7, 2023, 10:30 AM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies information for the presenter and planners/reviewers are below and in the presentation. All relevant financial relationships with ineligible companies have been mitigated.

Presenter

Dr Saag has reported consulting or advising fees from TFF Pharmaceuticals and American Gene Technologies, International, Inc. (Updated May 25, 2023).

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/